MCKESSON Business Summary

McKesson Corporation (NYSE: MCK) operates as a global leader in healthcare supply chain management and technology, generating revenue through a high-volume distribution model, service fees, and technology-driven clinical solutions. As of early 2026, the company operates through four primary reportable segments: North American Pharmaceutical, which manages large-scale drug distribution for retail and institutional providers; Oncology and Multispecialty, a high-growth segment providing specialty distribution and provider services; Prescription Technology Solutions, which facilitates medication access through digital biopharma networks; and Medical-Surgical Solutions, currently undergoing a strategic separation with a planned 2027 IPO. McKesson maintains a dominant position within the U.S. pharmaceutical distribution oligopoly, controlling a significant share of the domestic supply chain alongside its primary rivals, Cencora and Cardinal Health. It also competes with Henry Schein in the medical-surgical space and Oracle Health in healthcare IT, distinguishing itself through its massive scale and integrated oncology platform. Originally founded in 1833 by John McKesson and Charles Olcott, the company is led by Chief Executive Officer Brian S. Tyler, Ph.D., a 25-year veteran of the firm with a doctorate in economics from the University of Chicago. The executive leadership team includes Britt J. Vitalone, Executive Vice President and Chief Financial Officer, who expanded his remit in late 2023 to oversee the company’s technology organization and M&A strategy, and Francisco Fraga, who serves as Executive Vice President, Chief Information Officer, and Chief Technology Officer. The company’s governance is anchored by a Board of Directors chaired by Donald R. Knauss (former CEO of The Clorox Company) and includes notable independent directors such as Maria N. Martinez (former COO of Cisco) and Dominic J. Caruso (former CFO of Johnson & Johnson). McKesson maintains a robust institutional investor base, with approximately 85% of shares held by major asset managers, underscoring its role as a critical infrastructure provider in the global healthcare economy.